Misoprostol With or Without Letrozole in Treatment of Missed Miscarriage

NCT ID: NCT04593108

Last Updated: 2020-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

320 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-15

Study Completion Date

2020-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of study Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester.

Hypothesis:

Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester.

Research question:

Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim of the Work

Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester.

Hypothesis:

Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester.

Research question:

Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester?

Primary outcome:

Complete abortion (complete expulsion of products of conception with no need for curettage) within one week from the first dose of misoprostol.

Secondary outcome:

• Curettage (surgical evacuation of the products of conception)

* Incomplete abortion (retained products of conception).
* Considerable bleeding that necessitates immediate evacuation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Missed Abortion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Letrozole misoprostol

Group (A):

A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start

Letrozole misoprostol

Intervention Type DEVICE

Letrozole give pretreatment of abortion by misoprostol

Misoprostol,placebo

Group (B):

A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start

Misoprostol, placebo

Intervention Type DRUG

Give placebo pretreatment of abortion by misoprostol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Letrozole misoprostol

Letrozole give pretreatment of abortion by misoprostol

Intervention Type DEVICE

Misoprostol, placebo

Give placebo pretreatment of abortion by misoprostol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Woman age more than 18 years old (age of legal consent).
* BMI ranges between 25 kg/m2 and 35 kg/m2.
* Gestational age of 63 days' gestation (or less).
* Missed abortion.
* Hemoglobin leve

Exclusion Criteria

* Woman age less than 18 years old.
* BMI less than 25 kg/m2 or more than 35 kg/m2.
* Gestational age more than 63 days' gestation.
* Molar pregnancy.
* Hemoglobin level less than 10 gm/dL.
* Fibroid uterus.
* Uterus with congenital anomalies.
* Previous attempts for induction of abortion in the current pregnancy.
* Coagulation defect i.e. coagulopathy.
* Contraindication for induction of abortion e.g. heart failure.
* Allergy to misoprostol or letrozole.
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role collaborator

Dr.Dalia Mohammed Al Sayed Zaki

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr.Dalia Mohammed Al Sayed Zaki

Banha university

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zagazig General hospital, Ministry hospital

Role: PRINCIPAL_INVESTIGATOR

Zagazig general hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dalia Mohammed Al Sayed Zaki

Zagazig, Sharqia Province, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Lee VCY, Ng EHY, Yeung WSB, Ho PC. Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial. Obstet Gynecol. 2011 Feb;117(2 Pt 1):317-323. doi: 10.1097/AOG.0b013e3182073fbf.

Reference Type RESULT
PMID: 21252745 (View on PubMed)

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Individual Participant Data Set

Albrecht ED, Aberdeen GW, Pepe GJ, (2000). The role of estrogen in the maintenance of primate pregnancy. Am J Obstet Gynecol. 182:432-8. Albrecht ED, Robb VA, Pepe GJ, (2004). Regulation of placental vascular endothelial growth permeability factor expression and angiogenesis by estrogen during early baboon pregnancy. J Clin Endocrinol Metab. 89:

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/21252745/

Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Treatment of missedmiscarriage

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Termination Of Anembryonic Pregnancy
NCT02573051 WITHDRAWN PHASE2